DIRECT COST OF DIFFUSE TOXIC GOITER AND ITS COMPLICATIONS IN UKRAINE
Author(s)
Vadziuk I
Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine
Presentation Documents
OBJECTIVES To determine the direct cost of health care technologies used for treatment of diffuse toxic goiter in Ukraine. METHODS We made the retrospective analysis of 52 patients's medical records with DTG that were hospitalized to the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The method of pharmacoeconomic analysis "cost of illness" was used to estimate the cost of health care for patients with DTG While determining the direct costs of medical services in monetary terms we used the rates for medical services that were in Ternopil University Hospital. RESULTS The study found that among the patients there were 11 (21.15%) men and 41 (78.85%) women aged 20 to 65 years (46.88±8.9). All patients have got to the hospital in stage of medication subcompensation. The average duration of stay in hospital for patients was 10.67±2.07 days. The total cost of laboratory tests was EUR 1,555.53. The costs of instrumental methods of patients examination amounted EUR 204.25. The cost of consultations by specialists was EUR 285.97. In determining the amount of direct costs for medicines we found that the cost of drug treatment of the underlying disease is EUR 211.83, the cost of drug therapy of DTG complications is EUR 1,163.64. Total cost of patients stay in hospital was EUR 3,513.45. After calculation of all direct costs we determined that the total cost of DTG per patient is EUR 133.36 per course of treatment. CONCLUSIONS In the cost structure of health care provision for patients with diffuse toxic goiter the most significant costs were spent for laboratory tests and for patient's stay in hospital. The presence of underlying disease complications significantly increases cost of drugs.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PDB53
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders